Immunodiagnostic Systems Holdings plc (IDS) has reported revenues of GBP24.9 million for the fiscal 2009, up 51.4%, compared with the revenues of GBP16.4 million in the previous year. It also reported a profit attributable to equity holders of GBP4.82 million, or 18.569 pence per diluted share, for the fiscal 2009, compared with the profit attributable to equity holders of GBP2.8 million, or 13.489 pence per diluted share, in the previous year.
For the fiscal 2009, profit from continuing activities rose to GBP4.2 million from GBP2.8 million in the previous year. Earnings per share from continuing operations were 16.166 pence per share, up from 13.327 pence in the prior year. Pre-tax profit was GBP4.78 million, 27.1% higher than GBP3.76 million in the previous year.
The company said that the board proposed dividend for the year of 1.65 pence per share, up 10%, from prior year’s dividend of 1.50 pence per share, which is payable on August 21, 2009 to shareholders on the register on July 24, 2009.
IDS is a producer of diagnostic testing kits for the clinical and research markets, focusing on immunoassays used in the area of bone disease.